research Current Treatments for Alopecia Areata
There is no cure for alopecia areata, but treatments like JAK inhibitors show promise.
Search
for
Sort by
Research
420-450 / 1000+ resultsresearch Cosmeceutical and Dermatological Potential of Olive Mill Wastewater: A Sustainable and Eco-Friendly Source of Natural Ingredients
Olive mill wastewater can be used as a sustainable source of skin-benefiting ingredients.
research A Concept on The Development of The DRDE Series of Compounds for Skin Diseases Using In-Silico ADME And Drug-Likeness Analysis
DRDE-07 shows promise for treating skin diseases due to its favorable properties.
research Medical Technologies: Pharmaceutical Cosmetology, Cosmeceuticals – Opportunities and Limitations
Cosmeceuticals effectively treat skin issues but need better regulation and safety measures.
research Inflammatory Skin Disease in Latin America: Treatment Challenges and Opportunities
Improving education, training, and access to affordable treatments is crucial for better managing inflammatory skin diseases in Latin America.
research Herpes zoster ophthalmicus (HZO) secondary to platelet-rich plasma (PRP) therapy - A case report
A woman got a serious eye infection after a hair loss treatment due to improper procedure.
research A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
Monoclonal antibodies are often linked to alopecia areata cases.
research Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
LLLT devices for hair loss need more research to define proper guidelines.
research FDA Reports of Alopecia as an Adverse Event to Isotretinoin
Isotretinoin may cause hair loss, especially in women and young adults.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Finasteride may be linked to Peyronie’s disease, but more research is needed.
research FDA declines approval of testosterone drug for third time
The FDA rejected a testosterone drug again due to safety concerns.
research Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Finasteride is most linked to drug-induced erectile dysfunction.
research FDA Approved pediatric antihypertensive agents
FDA-approved medications are important for treating high blood pressure in children, but non-approved ones can be used if needed.
research (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
Finasteride may be linked to more psychiatric issues than dutasteride, but a definite cause isn't proven.
research Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study
Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
research Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
Certain medications, especially nervous system drugs, can cause insomnia, with risks varying by age and gender.
research Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
research Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
research Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
Many drugs can cause lipid metabolism issues, and labels need better warnings.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
research Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
Finasteride can cause long-term side effects like sexual dysfunction and depression.
research Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
Finasteride has various adverse effects, including sexual dysfunction and mental health issues, which vary by age and gender.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research FDA-Approved (Bremelanotide, Flibanserin) and Off-Label Medications (Testosterone, Sildenafil) to Enhance Sexual Desire/Function in Women
Some medications can help increase sexual desire and function in women.
research FDA approves label addition for PDE-5 inhibitor
The FDA approved using Cialis with Proscar for better treatment options.
research FDA declines approval of testosterone drug for third time
The FDA did not approve a testosterone drug because of safety concerns.